<DOC>
	<DOCNO>NCT00324389</DOCNO>
	<brief_summary>This proposal seek use DNA analysis understand racial genetic factor influence interferon ( treatment ) response HCV infection African Americans . A good understanding allow rational design new therapy well use exist therapy . Patients provide medical history undergo physical exam , blood draw , electrocardiogram , possible chest x-ray , abdominal ultrasound . Patients admit hospital 5 day undergo 2 liver biopsy , sedation , multiple blood draw . Twenty adult male volunteer ( 10 Caucasians,10 African Americans ) age 18 - 65 year participate .</brief_summary>
	<brief_title>Interferon-Induced Gene Expression Liver Cells Peripheral Blood Lymphocytes</brief_title>
	<detailed_description>This proposal use sophisticated DNA microarray analyse transcriptional change induce hepatocytes ( cellular locus viral replication ) peripheral blood lymphocyte ( one compartment immune responder cell ) effort well understand racial host genetic factor influence interferon response HCV infection . A good understanding underlying mechanism allow rational design new therapy well use exist therapeutic modality . The variable investigate racial difference interferon induce : 1 ) HCV viral kinetics 2 ) intrahepatic PBL transcriptional response . Specific Aim 1 : ( ) To compare phase 1 early phase 2 decline viral titer serum African-Americans Caucasians follow single dose IFN-alpha ( 10 MU sc ) . ( b ) To determine hepatic HCV RNA abundance baseline liver biopsy repeat liver biopsy take 24 hrs administration interferon , determine correlate HCV RNA decline serum 24 hr period . ( c ) To compare rate viral decline liver serum African-Americans Caucasians 24 hour interferon , relate pharmacokinetics ( PK ) initial dose interferon . A total 10 Caucasian 10 African American patient chronic hepatitis C HCV genotype 1 enrol study . All study patient undergo baseline percutaneous liver biopsy day 1 study . On day 3 , single dose IFN-alpha 2a ( 10 MU sc ) administer repeat liver biopsy do 24 hour injection . Specific Aim 2 : ( ) To utilize Affymetrix HG-U133A &amp; B Human GeneChips® determine global mRNA profile liver tissue collect patient 24 hrs single 10 MU dose IFN-alpha thereby assess intrahepatic transcriptional response IFN-alpha . ( b ) To characterize difference early intrahepatic transcriptional response interferon Caucasians African Americans . Specific Aim 3 : ( ) To utilize Affymetrix HG-U133A &amp; B Human GeneChips® determine global transcription profile peripheral blood lymphocytes pre-treatment , 24hrs , 48hrs initial dose interferon compare result Caucasians African Americans time point . ( b ) To compare global gene profile lymphocytes liver baseline 24hrs interferon , determine whether lymphocytic transcriptional profiling valid surrogate intrahepatic gene profiling . Specific Aim 4 : To use sophisticated bioinformatics approach HCV kinetic modeling determine whether difference early intrahepatic lymphocytic transcriptional profile correlate early change level viremia ( observed antiviral response ) period immediately follow administration 10 MU dose IFN-alpha .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Male nonHispanic AfricanAmerican nonHispanic Caucasian patient 18 65 year age 2 . Abstinence ingestion alcohol smoking least 7 day prior study drink smoke socially 3 . HCV genotype 1 ( 1a , 1b mixture 1a 1b ) . HCV genotyping perform Molecular Diagnostic Laboratory UTMB use LiPA assay ( Innogenetics ) 4 . Presence HCV RNA serum ( &gt; 10 [ fifth power ] copies/ml ) 5 . Not previously treat interferon and/ ribavirin 6 . Compensated liver disease follow laboratory criterion : Hemoglobin great equal 13 gm/dl male Granulocyte count great equal 1,000/cubic mm Platelets great equal 100,000/cubic mm Prothrombin time &lt; 2 sec . elevation Total bilirubin ( 0.11.1 mg/dl ) . If elevate , conjugate Bilirubin must within normal limit ( 00.3 mg/dl ) Serum albumin within normal limit ( 3.55.0 g/dl ) Serum creatinine within normal limit ( 0.71.7 mg/ml ) 7 . Absence known cause liver disease ( e.g . autoimmune hepatitis , hemochromatosis , Wilson 's disease , alpha1 antitrypsin deficiency , druginduced liver injury , alcoholic liver disease ) 8 . No systemic antiviral immunosuppressive therapy within last 6 month 9 . Absence concurrent medical psychiatric illness ( e.g . viral coinfection HBV HIV , renal failure , poorly control diabetes , cardiacpulmonary disease , CNS disease , active alcoholism , depression , psychosis ) 10 . No history Type 1 Type 2 diabetes mellitis 11 . TSH within normal limit ( 0.494.7 micro IU/ml ) 12 . ANA &lt; 1:160 13 . No history hepatocellular carcinoma 14 . Alpha fetoprotein within normal limit ( 020 ng/ml ) obtain within 6 month enrollment . 15 . If participate sexual activity could lead pregnancy , study volunteer must agree two reliable method contraception use partner simultaneously receive medication , 6 month stop medication . The following consider reliable effective method birth control . 1 ) Condoms without spermicidal agent 2 ) Diaphragm cervical cap spermicide 3 ) IUD 4 ) Hormonalbased contraception 16 . Exceptions may include study participant/partner surgically sterile 17 . Willingness comply procedure treatment outline protocol provide write informed consent 1 . Interferon ribavirin therapy previous time 2 . Any investigational drug &lt; = 24 week prior first dose study drug 3 . Any alternative folk medicine within 24 week screen 4 . Any systemic antiviral therapy &lt; = 24 week prior first dose study drug expectation treatment need time study . Exception : patient take expected require acyclovir herpetic lesion 5 . Patient baseline increase risk anemia ( e.g . hemoglobinopathy thalassemia , spherocytosis , sickle cell anemia history symptomatic recur GI bleeding , etc . ) anemia would medically problematic 6 . Evidence alcohol and/or drug abuse within 6 month 7 . History immunologically mediate disease ( e.g. , inflammatory bowel disease , idiopathic thrombocytopenic purpura , lupus erythematosus , autoimmune hemolytic anemia , scleroderma , severe psoriasis , clinical evidence rheumatoid arthritis ) 8 . Evidence active suspect cancer history malignancy 9 . History receive systemic antineoplastic immunomodulatory treatment ( include supraphysiologic dos steroid radiation ) &lt; = 6 month prior first dose study drug expectation treatment need time study 10 . History major organ transplantation exist functional graft 11 . History bone marrow transplantation 12 . Anything opinion investigator put patient increase risk , increase likelihood patient may able complete protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Interferon , Gene Expression Liver , Lymphocytes , High Density Oligonucleotide Microarray Expression Analysis , African American , Hepatitis C</keyword>
</DOC>